Hélène Koch

My research focuses on the design of treatment combination strategies to mitigate the impact of radioresistance on the outcome of radioligand therapy, namely ¹⁷⁷Lu-PSMA-617, in prostate cancer. This will help understand the underlying mechanisms that drive tumor resistance and recurrence. Finding synergistic drug combinations will also help improve treatment plans for patients and providing more tumor- and patient specific personalized cancer care. To achieve this, I will run in vivo experiments with multiple clinically approved drugs that impact diverse aspects of the tumor burden and select the most promising candidates for radiosensitization.